REFERENCES
- Panagiotou S, Hatzoglou A, Calvo F, Martin PM, Castanas E. Modulation of the estrogen-regulated proteins cathepsin D and pS2 by opioid agonists in hormone-sensitive breast cancer cell lines (MCF7 and T47D): evidence for an interaction between the two systems. J Cell Biochem 1998; 71:416–428.
- Eckert RL, Katzenellenbogen BS. Effect of estrogens and antiestrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. Cancer Res 1982; 42:139–144.
- Tso CL, McBride WH, Sun J, Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 2000; 6(4):220–233.
- Raffo AJ, Perlman H, Chen MW, Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55:4438–4445.
- Samuels HH, Stanley F, Casanova J. Depletion of l-3,5,3′-triiodothyronine and l-thyroxine in euthyroid calf serum for use in cell culture studies of the action of thyroid hormone. Endocrinology 1979; 105:80–85.
- Liby K, Neltner B, Mohamet L, Menchen L, Ben-Jonathan N. Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Res Treat 2003; 79:241–252.
- Bahk JY, Hyun JS, Lee H, Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells. Urol Res 1998; 26:259–264.
- Cos S, Sanchez-Barcelo EJ. Melatonin inhibition of MCF-7 human breast-cancer cells growth: influence of cell proliferation rate. Cancer Lett 1995; 93:207–212.
- Uhlenbrock K, Gassenhuber H, Kostenis E. Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors. Cell Signal 2002; 14:941–953.
- Dang ZC, Lowik CW. Removal of serum factors by charcoal treatment promotes adipogenesis via a MAPK-dependent pathway. Mol Cell Biochem 2005; 268:159–167.
- Burchardt T, Burchardt M, Chen MW, Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999; 162:1800–1805.
- Lin H-Y, Thacore HR, Davis PJ, Davis FB. Thyroid hormone potentiates the antiviral action of interferon-gamma in cultured human cells. J Clin Endocrinol Metab 1994; 79:62–65.
- US Department of Health and Human Services. Medicare, Medicaid and CLIA programs: regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA), final rule. Fed Regist 1992; 57:7002–7186.
- Spink DC, Katz BH, Hussain MM, Pentecost BT, Cao Z, Spink BC. Estrogen regulates Ah responsiveness in MCF-7 breast cancer cells. Carcinogenesis 2003; 24:1941–1950.
- Vignon F, Rochefort H. Nuclear translocation of the estrogen receptor in autonomous C3H mouse mammary tumors. Cancer Res 1978; 38:1808–1814.
- Vignon F, Terqui M, Westley B, Derocq D, Rochefort H. Effects of plasma estrogen sulfates in mammary cancer cells. Endocrinology 1980; 106:1079–1086.